Citius Pharmaceuticals
Open
$0.55
Prev. Close
$0.55
High
$0.55
Low
$0.55
Market Snapshot
$12.12M
-0.3
-5.81
23
Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is headquartered in Cranford, New Jersey and currently employs 23 full-time employees. The company went IPO on 2017-08-03. The firm's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The firm is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.
Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is headquartered in Cranford, New Jersey and currently employs 23 full-time employees. The company went IPO on 2017-08-03. The firm's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The firm is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.
Recently from Cashu
Citius Pharmaceuticals Innovates Novel Treatments for CLABSI and Oncology Challenges
Citius Pharmaceuticals Advances Innovative Treatment Approaches Citius Pharmaceuticals continues to make strides in the development of innovative medicinal solutions, particularly focusing on critical…
Citius Pharmaceuticals Secures $3.8 Million to Advance Critical Care Product Development
Citius Pharmaceuticals Secures $3.8 Million to Advance Critical Care Product Development Citius Pharmaceuticals, Inc. announces a significant financial boost of $3.8 million through New Jersey's Techn…
Citius Pharmaceuticals Gains $3.8 Million to Advance Critical Care Products Through NOL Program
Citius Pharmaceuticals Secures $3.8 Million Through NOL Program to Advance Critical Care Products Citius Pharmaceuticals, Inc. focuses on developing critical care products and has recently secured $3.…
Citius Pharmaceuticals: Innovating Cancer Care with Mino-Lok and Collaborative Research Efforts
Citius Pharmaceuticals: Pioneering Progress in Cancer Treatment Citius Pharmaceuticals is making significant strides in the field of oncology, focusing on innovative therapies that address critical ga…